Pediatric Cancer
Massey Cancer Center Researchers Exploring SHP2 Inhibitor Potential in Pediatric Neuroblastoma
Premium
Based on data from tumor models, researchers are working with the NCI to explore the potential of SHP2 inhibitors with maintenance therapy in high-risk neuroblastoma with NF1 loss.
Pfizer's Xalkori Gets FDA Approval for ALK-Positive Inflammatory Myofibroblastic Tumors
The agency approved the drug to treat both adult and pediatric patients with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors.
NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.Â
Structural Variant Study Points to Pediatric Glioma Drivers, Prognostic Features
Researchers profiled structural variant patterns in 179 pediatric high-grade glioma cases, identifying SV features linked to tumor subtypes and clinical outcomes.
Day One Bio Raises $150M in Public Offering of Common Stock
The funds will be used to support two ongoing Phase II clinical trials and to begin a Phase III study off its lead candidate tovorafenib in newly diagnosed pediatric glioma.